デフォルト表紙
市場調査レポート
商品コード
1428435

オピオイド使用障害(OUD)の世界市場レポート 2024年

Opioid Use Disorder (OUD) Global Market Report 2024

出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.56円
オピオイド使用障害(OUD)の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 目次
概要

オピオイド使用障害(OUD)の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には11.3%の年間複合成長率(CAGR)で60億4,000万米ドルに成長すると予想されます。予測期間で予想される成長は、オピオイド関連問題への対処を目的とした規制介入、代替疼痛管理戦略への注目の高まり、治療へのアクセス拡大への取り組み、さまざまな公衆衛生への取り組みなど、いくつかの要因によるものと考えられます。この期間中に予想される主要動向には、治療法の技術革新、個別化された治療アプローチへの移行、統合ケアモデルの導入、地域ベースの支援プログラムの開発、早期介入と予防策の重視などが含まれます。これらの動向は、オピオイドの使用と依存症に関連する課題に取り組むための包括的かつ進化するアプローチを総合的に反映しています。

オピオイド中毒の症例数は増加しており、オピオイド使用障害(OUD)市場の拡大を促進する態勢が整っています。オピオイド中毒とは、身体に悪影響を及ぼす、オピオイドの持続的かつ強迫的な使用を特徴とする病状を指します。これらの物質は多幸感や鎮痛を誘発することが多く、時間が経つにつれて耐性が高まり、同じ効果を達成するにはより高い用量が必要となり、オピオイド使用障害を引き起こす可能性があります。たとえば、2022年5月の疾病管理予防センターのデータによると、米国におけるオピオイドの過剰摂取による死亡者数は15%増加し、2020年の7万29人から2021年には8万816人に増加しました。

慢性疾患の有病率の急増により、オピオイド使用障害(OUD)市場の拡大が促進されると予想されます。慢性疾患は1年以上持続するため、継続的な治療が必要となり、日常生活が制限されることがよくあります。がん、関節炎、またはその他の長期にわたる病気に伴う激しい痛みなどの多くの慢性疾患では、効果的な疼痛管理のためにオピオイド薬の使用が必要になることがよくあります。たとえば、国立バイオテクノロジー情報センター(NCBI)が2023年 1月に発表した予測では、少なくとも1つの慢性疾患に苦しむ50歳以上の人の数は2050年までに99.5%という驚異的な増加となり、1年の7,152万2,000人から増加すると推定されています。 2020年には1億4,266万人になり、慢性疾患有病率の急増は、オピオイド使用障害(OUD)市場の成長の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界のオピオイド使用障害(OUD)市場の促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界のオピオイド使用障害(OUD)の市場規模実績と成長、2018~2023年
  • 世界のオピオイド使用障害(OUD)市場規模と成長予測、2023~2028年、2033年

第6章 市場セグメンテーション

  • 世界のオピオイド使用障害(OUD)市場、薬剤タイプ別セグメンテーション、実績と予測、2018~2023年、2023~2028年、2033年
  • ブプレノルフィン
  • ナルトレキソン
  • メタドン
  • 世界のオピオイド使用障害(OUD)市場、投与経路別セグメンテーション、実績と予測、2018~2023年、2023~2028年、2033年
  • 経口
  • 非経口
  • 世界のオピオイド使用障害(OUD)市場、年齢層別セグメンテーション、実績と予測、2018~2023年、2023~2028年、2033年
  • 19~40歳
  • 41~60歳
  • 61歳以上
  • 世界のオピオイド使用障害(OUD)市場、流通チャネル別セグメンテーション、実績と予測、2018~2023年、2023~2028年、2033年
  • 病院薬局
  • 小売薬局と店舗
  • オンライン薬局

第7章 地域と国の分析

  • 世界のオピオイド使用障害(OUD)市場、地域別、実績と予測、2018~2023年、2023~2028年、2033年
  • 世界のオピオイド使用障害(OUD)市場、国別、実績と予測、2018~2023年、2023~2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • オピオイド使用障害(OUD)市場の競合情勢
  • オピオイド使用障害(OUD)市場の企業プロファイル
    • Pfizer Inc.
    • Novartis AG
    • AstraZeneca plc.
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.

第31章 その他の大手と革新的な企業

  • Chiesi Pharmaceuticals SpA
  • Hikma Pharmaceuticals Plc.
  • Mallinckrodt Pharmaceuticals
  • Indivior Plc.
  • Knight Therapeutics Inc.
  • Purdue Pharma LP
  • Alkermes Inc.
  • Collegium Pharmaceutical Inc.
  • Vanda Pharmaceuticals Inc.
  • Camurus AB
  • Tris Pharma Inc.
  • Mylan NV.
  • Orexo US Inc.
  • Zogenix Inc.
  • Rhodes Pharmaceuticals LP

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

目次
Product Code: r14280

Opioid use disorder (OUD) is a chronic brain disease that stems from prolonged use of opioids, encompassing both prescription painkillers and illegal opioids. The development of opioid use disorder is influenced by a combination of genetic, environmental, and behavioral factors.

The primary medications for treating opioid use disorder (OUD) include buprenorphine, naltrexone, and methadone. Buprenorphine, classified as an opioid, is utilized in the management of opioid use disorder to mitigate cravings and alleviate withdrawal symptoms associated with opioid dependence. This medication is administered through oral and parenteral routes and is applicable across various age groups, including those aged 19 to 40, 41 to 60, and 61 and over. Distribution channels for buprenorphine include hospital pharmacies, retail pharmacies and stores, as well as online pharmacies.

The opioid use disorder (OUD) research report is one of a series of new reports from The Business Research Company that provides opioid use disorder (OUD) market statistics, including the opioid use disorder (OUD) industry's global market size, regional shares, competitors with opioid use disorder (OUD) market share, detailed opioid use disorder (OUD) market segments, market trends and opportunities, and any further data you may need to thrive in the opioid use disorder (OUD) industry. This opioid use disorder (OUD) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The opioid use disorder (oud) market size has grown rapidly in recent years. It will grow from $3.53 billion in 2023 to $3.93 billion in 2024 at a compound annual growth rate (CAGR) of 11.3%. The growth observed in the historical period can be attributed to several factors, including an increase in prescription rates for opioid medications, evolving pain management practices, the impact of drug marketing, and the stigmatization associated with addiction. These factors collectively contributed to the patterns and challenges related to opioid use and addiction during the specified historical timeframe.

The opioid use disorder (oud) market size is expected to see rapid growth in the next few years. It will grow to $6.04 billion in 2028 at a compound annual growth rate (CAGR) of 11.3%. The anticipated growth in the forecast period can be attributed to several factors, including regulatory interventions aimed at addressing opioid-related issues, an increased focus on alternative pain management strategies, efforts to expand access to treatment, and various public health initiatives. Key trends expected during this period encompass technological innovations in treatment methods, a shift toward individualized treatment approaches, the implementation of integrated care models, the development of community-based support programs, and an emphasis on early intervention and prevention measures. These trends collectively reflect a comprehensive and evolving approach to tackling the challenges associated with opioid use and addiction.

The escalating number of opioid addiction cases is poised to drive the expansion of the opioid use disorder (OUD) market. Opioid addiction denotes a medical condition characterized by persistent and compulsive use of opioids, leading to adverse effects on the body. These substances often induce euphoria and pain relief, fostering tolerance over time, wherein higher doses are necessary to achieve the same effects, potentially resulting in opioid use disorder. For example, data from the Centers for Disease Control and Prevention in May 2022 revealed a 15% increase in opioid overdose deaths in the USA, rising from 70,029 in 2020 to 80,816 in 2021. Thus, the mounting occurrences of opioid addiction cases are fueling the growth of the opioid use disorder (OUD) market.

The upsurge in the prevalence of chronic diseases is anticipated to propel the expansion of the opioid use disorder (OUD) market. Chronic diseases persist for a year or longer, demanding continuous medical attention and often limiting daily activities. Many chronic conditions, such as severe pain associated with cancer, arthritis, or other long-term ailments, frequently necessitate the use of opioid medications for effective pain management. For instance, projections from the National Centre for Biotechnology Information (NCBI) in January 2023 estimated a staggering 99.5% increase by the year 2050 in the number of individuals aged 50 years and older afflicted with at least one chronic illness, rising from 71.522 million in 2020 to 142.66 million. Thus, the surge in chronic disease prevalence is a driving force behind the growth of the opioid use disorder (OUD) market.

Product innovation stands out as a significant and increasingly favored trend in the opioid use disorder (OUD) market. Major companies operating within this sector are actively engaged in developing innovative products to maintain their market standing. An illustrative instance occurred in May 2023 when the U.S. Food and Drug Administration, a federal agency in the United States, granted approval for Brixadi (buprenorphine) extended-release injection to address moderate to severe cases of opioid use disorder (OUD). Brixadi is available in two dosage forms such as a weekly injection designed for patients commencing treatment with a single dose of transmucosal buprenorphine or those presently using the medication, and a monthly version tailored for individuals already receiving this treatment.

Prominent entities in the opioid use disorder (OUD) market are focused on forging strategic alliances to bolster their market position. Strategic alliances, taking diverse forms, aim to yield mutual benefits and fortify the market positions of the participating companies. An exemplar of this strategy occurred in March 2023, as Harm Reduction Therapeutics, a non-profit pharmaceutical company based in the United States, partnered with Catalent, Inc., a company specializing in developing and delivering advanced treatments globally. Within this collaboration, Catalent, Inc. will undertake the manufacturing of RiVive (3.0 mg), a naloxone nasal spray intended for harm reduction therapy, facilitating emergency treatment for known or suspected opioid overdose cases. This alliance was driven by the urgent need to address the ongoing opioid epidemic on a national scale. The goal behind developing an over-the-counter naloxone solution is to significantly broaden access, making naloxone more readily available to save lives imperiled by opioid overdoses.

In March 2023, the US-based pharmaceutical company Indivior plc successfully completed the acquisition of Opiant Pharmaceuticals Inc. for a total of $145 million. This strategic move is poised to enhance Indivior's product portfolio in the addiction treatment sector, fortifying its position in the market. Opiant Pharmaceuticals Inc., the acquired entity, is also based in the United States and specializes in the development of pharmaceuticals targeted at addressing opioid overdose, acute cannabinoid overdose, and opioid use disorder.

Major companies operating in the opioid use disorder (oud) market report are Pfizer Inc., Novartis AG, AstraZeneca plc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Chiesi Pharmaceuticals S.p.A., Hikma Pharmaceuticals Plc., Mallinckrodt Pharmaceuticals, Indivior Plc., Knight Therapeutics Inc., Purdue Pharma L.P, Alkermes Inc., Collegium Pharmaceutical Inc., Vanda Pharmaceuticals Inc., Camurus AB, Tris Pharma Inc., Mylan NV., Orexo US Inc., Zogenix Inc., Rhodes Pharmaceuticals L.P., Omeros Corporation, Braeburn Pharmaceuticals Inc., Adapt Pharma Inc., Titan Pharmaceuticals Inc., BioDelivery Sciences International Inc., Insys Therapeutics Inc., MediciNova Inc., Cara Therapeutics Inc., AcelRx Pharmaceuticals Inc., KemPharm Inc.,

North America was the largest region in the opioid use disorder (OUD) market in 2023. The regions covered in the opioid use disorder (oud) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the opioid use disorder (oud) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The opioid use disorder (OUD) market consists of sales of bunavail, sublocade, suboxone, and zubsolv. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Opioid Use Disorder (OUD) Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on opioid use disorder (oud) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for opioid use disorder (oud) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The opioid use disorder (oud) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Drug Type: Buprenorphine; Naltrexone; Methadone
  • 2) By Route of Administration: Oral; Parenteral
  • 3) By Age Group: 19 To 40; 41 To 60; 61 And Over
  • 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies And Stores; Online Pharmacies
  • Companies Mentioned: Pfizer Inc.; Novartis AG; AstraZeneca plc.; Viatris Inc.; Teva Pharmaceutical Industries Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Opioid Use Disorder (OUD) Market Characteristics

3. Opioid Use Disorder (OUD) Market Trends And Strategies

4. Opioid Use Disorder (OUD) Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Opioid Use Disorder (OUD) Market Size and Growth

  • 5.1. Global Opioid Use Disorder (OUD) Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Opioid Use Disorder (OUD) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Opioid Use Disorder (OUD) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Opioid Use Disorder (OUD) Market Segmentation

  • 6.1. Global Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Buprenorphine
  • Naltrexone
  • Methadone
  • 6.2. Global Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Parenteral
  • 6.3. Global Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19 To 40

41 To 60

61 And Over

  • 6.4. Global Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies And Stores
  • Online Pharmacies

7. Opioid Use Disorder (OUD) Market Regional And Country Analysis

  • 7.1. Global Opioid Use Disorder (OUD) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Opioid Use Disorder (OUD) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Opioid Use Disorder (OUD) Market

  • 8.1. Asia-Pacific Opioid Use Disorder (OUD) Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Opioid Use Disorder (OUD) Market

  • 9.1. China Opioid Use Disorder (OUD) Market Overview
  • 9.2. China Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Opioid Use Disorder (OUD) Market

  • 10.1. India Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Opioid Use Disorder (OUD) Market

  • 11.1. Japan Opioid Use Disorder (OUD) Market Overview
  • 11.2. Japan Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Opioid Use Disorder (OUD) Market

  • 12.1. Australia Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Opioid Use Disorder (OUD) Market

  • 13.1. Indonesia Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Opioid Use Disorder (OUD) Market

  • 14.1. South Korea Opioid Use Disorder (OUD) Market Overview
  • 14.2. South Korea Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Opioid Use Disorder (OUD) Market

  • 15.1. Western Europe Opioid Use Disorder (OUD) Market Overview
  • 15.2. Western Europe Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Opioid Use Disorder (OUD) Market

  • 16.1. UK Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Opioid Use Disorder (OUD) Market

  • 17.1. Germany Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Opioid Use Disorder (OUD) Market

  • 18.1. France Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Opioid Use Disorder (OUD) Market

  • 19.1. Italy Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Opioid Use Disorder (OUD) Market

  • 20.1. Spain Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Opioid Use Disorder (OUD) Market

  • 21.1. Eastern Europe Opioid Use Disorder (OUD) Market Overview
  • 21.2. Eastern Europe Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Opioid Use Disorder (OUD) Market

  • 22.1. Russia Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Opioid Use Disorder (OUD) Market

  • 23.1. North America Opioid Use Disorder (OUD) Market Overview
  • 23.2. North America Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Opioid Use Disorder (OUD) Market

  • 24.1. USA Opioid Use Disorder (OUD) Market Overview
  • 24.2. USA Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Opioid Use Disorder (OUD) Market

  • 25.1. Canada Opioid Use Disorder (OUD) Market Overview
  • 25.2. Canada Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Opioid Use Disorder (OUD) Market

  • 26.1. South America Opioid Use Disorder (OUD) Market Overview
  • 26.2. South America Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Opioid Use Disorder (OUD) Market

  • 27.1. Brazil Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Opioid Use Disorder (OUD) Market

  • 28.1. Middle East Opioid Use Disorder (OUD) Market Overview
  • 28.2. Middle East Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Opioid Use Disorder (OUD) Market

  • 29.1. Africa Opioid Use Disorder (OUD) Market Overview
  • 29.2. Africa Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Opioid Use Disorder (OUD) Market Competitive Landscape And Company Profiles

  • 30.1. Opioid Use Disorder (OUD) Market Competitive Landscape
  • 30.2. Opioid Use Disorder (OUD) Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Novartis AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. AstraZeneca plc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Viatris Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Teva Pharmaceutical Industries Ltd.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Opioid Use Disorder (OUD) Market Other Major And Innovative Companies

  • 31.1. Chiesi Pharmaceuticals S.p.A.
  • 31.2. Hikma Pharmaceuticals Plc.
  • 31.3. Mallinckrodt Pharmaceuticals
  • 31.4. Indivior Plc.
  • 31.5. Knight Therapeutics Inc.
  • 31.6. Purdue Pharma L.P
  • 31.7. Alkermes Inc.
  • 31.8. Collegium Pharmaceutical Inc.
  • 31.9. Vanda Pharmaceuticals Inc.
  • 31.10. Camurus AB
  • 31.11. Tris Pharma Inc.
  • 31.12. Mylan NV.
  • 31.13. Orexo US Inc.
  • 31.14. Zogenix Inc.
  • 31.15. Rhodes Pharmaceuticals L.P.

32. Global Opioid Use Disorder (OUD) Market Competitive Benchmarking

33. Global Opioid Use Disorder (OUD) Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Opioid Use Disorder (OUD) Market

35. Opioid Use Disorder (OUD) Market Future Outlook and Potential Analysis

  • 35.1 Opioid Use Disorder (OUD) Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Opioid Use Disorder (OUD) Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Opioid Use Disorder (OUD) Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer